

Blood-Brain Barrier Transport Drugs-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/BD2F84D4415EN.html>

Date: February 2018

Pages: 148

Price: US\$ 3,480.00 (Single User License)

ID: BD2F84D4415EN

Abstracts

Report Summary

Blood-Brain Barrier Transport Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Blood-Brain Barrier Transport Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Blood-Brain Barrier Transport Drugs 2013-2017, and development forecast 2018-2023

Main market players of Blood-Brain Barrier Transport Drugs in EMEA, with company and product introduction, position in the Blood-Brain Barrier Transport Drugs market
Market status and development trend of Blood-Brain Barrier Transport Drugs by types and applications

Cost and profit status of Blood-Brain Barrier Transport Drugs, and marketing status
Market growth drivers and challenges

The report segments the EMEA Blood-Brain Barrier Transport Drugs market as:

EMEA Blood-Brain Barrier Transport Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Blood-Brain Barrier Transport Drugs Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Carrier-mediated Transport
Receptor-mediated Transport
Absorptive-mediated Transport
Active Efflux Transport
Others

EMEA Blood-Brain Barrier Transport Drugs Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Alzheimer's Disease
Epilepsy
Parkinson's Disease
Multiple Sclerosis
Hunter's Syndrome
Brain Cancer
Others

EMEA Blood-Brain Barrier Transport Drugs Market: Players Segment Analysis
(Company and Product introduction, Blood-Brain Barrier Transport Drugs Sales Volume, Revenue, Price and Gross Margin):

Cyclenium
BioAdvance
EIP Pharma
Bioasis
Immune Pharmaceuticals
AZ Therapies
Palobiofarma
Bach Pharma
BrainsGate
CarThera
Dainippon Sumitomo Pharma
Fluorinov Pharma

Fondazione Telethon
Minoryx
NewGen Therapeutics

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF BLOOD-BRAIN BARRIER TRANSPORT DRUGS

- 1.1 Definition of Blood-Brain Barrier Transport Drugs in This Report
- 1.2 Commercial Types of Blood-Brain Barrier Transport Drugs
 - 1.2.1 Carrier-mediated Transport
 - 1.2.2 Receptor-mediated Transport
 - 1.2.3 Absorptive-mediated Transport
 - 1.2.4 Active Efflux Transport
 - 1.2.5 Others
- 1.3 Downstream Application of Blood-Brain Barrier Transport Drugs
 - 1.3.1 Alzheimer's Disease
 - 1.3.2 Epilepsy
 - 1.3.3 Parkinson's Disease
 - 1.3.4 Multiple Sclerosis
 - 1.3.5 Hunter's Syndrome
 - 1.3.6 Brain Cancer
 - 1.3.7 Others
- 1.4 Development History of Blood-Brain Barrier Transport Drugs
- 1.5 Market Status and Trend of Blood-Brain Barrier Transport Drugs 2013-2023
 - 1.5.1 EMEA Blood-Brain Barrier Transport Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Blood-Brain Barrier Transport Drugs Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Blood-Brain Barrier Transport Drugs in EMEA 2013-2017
- 2.2 Consumption Market of Blood-Brain Barrier Transport Drugs in EMEA by Regions
 - 2.2.1 Consumption Volume of Blood-Brain Barrier Transport Drugs in EMEA by Regions
 - 2.2.2 Revenue of Blood-Brain Barrier Transport Drugs in EMEA by Regions
- 2.3 Market Analysis of Blood-Brain Barrier Transport Drugs in EMEA by Regions
 - 2.3.1 Market Analysis of Blood-Brain Barrier Transport Drugs in Europe 2013-2017
 - 2.3.2 Market Analysis of Blood-Brain Barrier Transport Drugs in Middle East 2013-2017
 - 2.3.3 Market Analysis of Blood-Brain Barrier Transport Drugs in Africa 2013-2017
- 2.4 Market Development Forecast of Blood-Brain Barrier Transport Drugs in EMEA 2018-2023

2.4.1 Market Development Forecast of Blood-Brain Barrier Transport Drugs in EMEA 2018-2023

2.4.2 Market Development Forecast of Blood-Brain Barrier Transport Drugs by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole EMEA Market Status by Types

3.1.1 Consumption Volume of Blood-Brain Barrier Transport Drugs in EMEA by Types

3.1.2 Revenue of Blood-Brain Barrier Transport Drugs in EMEA by Types

3.2 EMEA Market Status by Types in Major Countries

3.2.1 Market Status by Types in Europe

3.2.2 Market Status by Types in Middle East

3.2.3 Market Status by Types in Africa

3.3 Market Forecast of Blood-Brain Barrier Transport Drugs in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Blood-Brain Barrier Transport Drugs in EMEA by Downstream Industry

4.2 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry in Major Countries

4.2.1 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry in Europe

4.2.2 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry in Middle East

4.2.3 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry in Africa

4.3 Market Forecast of Blood-Brain Barrier Transport Drugs in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BLOOD-BRAIN BARRIER TRANSPORT DRUGS

5.1 EMEA Economy Situation and Trend Overview

5.2 Blood-Brain Barrier Transport Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 BLOOD-BRAIN BARRIER TRANSPORT DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Blood-Brain Barrier Transport Drugs in EMEA by Major Players
- 6.2 Revenue of Blood-Brain Barrier Transport Drugs in EMEA by Major Players
- 6.3 Basic Information of Blood-Brain Barrier Transport Drugs by Major Players
 - 6.3.1 Headquarters Location and Established Time of Blood-Brain Barrier Transport Drugs Major Players
 - 6.3.2 Employees and Revenue Level of Blood-Brain Barrier Transport Drugs Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 BLOOD-BRAIN BARRIER TRANSPORT DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Cyclenium
 - 7.1.1 Company profile
 - 7.1.2 Representative Blood-Brain Barrier Transport Drugs Product
 - 7.1.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Cyclenium
- 7.2 BioAdvance
 - 7.2.1 Company profile
 - 7.2.2 Representative Blood-Brain Barrier Transport Drugs Product
 - 7.2.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of BioAdvance
- 7.3 EIP Pharma
 - 7.3.1 Company profile
 - 7.3.2 Representative Blood-Brain Barrier Transport Drugs Product
 - 7.3.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of EIP Pharma
- 7.4 Bioasis
 - 7.4.1 Company profile
 - 7.4.2 Representative Blood-Brain Barrier Transport Drugs Product
 - 7.4.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Bioasis
- 7.5 Immune Pharmaceuticals

- 7.5.1 Company profile
- 7.5.2 Representative Blood-Brain Barrier Transport Drugs Product
- 7.5.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Immune Pharmaceuticals
- 7.6 AZ Therapies
 - 7.6.1 Company profile
 - 7.6.2 Representative Blood-Brain Barrier Transport Drugs Product
 - 7.6.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of AZ Therapies
- 7.7 Palobiofarma
 - 7.7.1 Company profile
 - 7.7.2 Representative Blood-Brain Barrier Transport Drugs Product
 - 7.7.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Palobiofarma
- 7.8 Bach Pharma
 - 7.8.1 Company profile
 - 7.8.2 Representative Blood-Brain Barrier Transport Drugs Product
 - 7.8.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Bach Pharma
- 7.9 BrainsGate
 - 7.9.1 Company profile
 - 7.9.2 Representative Blood-Brain Barrier Transport Drugs Product
 - 7.9.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of BrainsGate
- 7.10 CarThera
 - 7.10.1 Company profile
 - 7.10.2 Representative Blood-Brain Barrier Transport Drugs Product
 - 7.10.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of CarThera
- 7.11 Dainippon Sumitomo Pharma
 - 7.11.1 Company profile
 - 7.11.2 Representative Blood-Brain Barrier Transport Drugs Product
 - 7.11.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Dainippon Sumitomo Pharma
- 7.12 Fluorinov Pharma
 - 7.12.1 Company profile
 - 7.12.2 Representative Blood-Brain Barrier Transport Drugs Product
 - 7.12.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Fluorinov Pharma

7.13 Fondazione Telethon

7.13.1 Company profile

7.13.2 Representative Blood-Brain Barrier Transport Drugs Product

7.13.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Fondazione Telethon

7.14 Minoryx

7.14.1 Company profile

7.14.2 Representative Blood-Brain Barrier Transport Drugs Product

7.14.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Minoryx

7.15 NewGen Therapeutics

7.15.1 Company profile

7.15.2 Representative Blood-Brain Barrier Transport Drugs Product

7.15.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of NewGen Therapeutics

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BLOOD-BRAIN BARRIER TRANSPORT DRUGS

8.1 Industry Chain of Blood-Brain Barrier Transport Drugs

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BLOOD-BRAIN BARRIER TRANSPORT DRUGS

9.1 Cost Structure Analysis of Blood-Brain Barrier Transport Drugs

9.2 Raw Materials Cost Analysis of Blood-Brain Barrier Transport Drugs

9.3 Labor Cost Analysis of Blood-Brain Barrier Transport Drugs

9.4 Manufacturing Expenses Analysis of Blood-Brain Barrier Transport Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF BLOOD-BRAIN BARRIER TRANSPORT DRUGS

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

- 10.2.1 Pricing Strategy
- 10.2.2 Brand Strategy
- 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Blood-Brain Barrier Transport Drugs-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/BD2F84D4415EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BD2F84D4415EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970